Navigation Links
New Latent TB Drug Saves Lives, Money
Date:5/20/2008

Rifampin improved compliance, reduced side effects, saved $10,000 per patient

TUESDAY, May 20 (HealthDay News) -- Using the drug Rifampin to treat people with latent tuberculosis saves time, money and lives, new research shows.

"We found that using a therapy of four months of Rifampin instead of the current nine months of Isoniazid costs significantly less for the health-care system," lead analyst Anne Aspler, of the respiratory epidemiology and clinical research unit at McGill University's Montreal Chest Clinic, said in a prepared statement.

"Overall, Rifampin costs about $484 less per patient treated, which, if we assume that four months of Rifampin has a least equal efficacy to nine months of Isoniazid, represents an added savings to the health system of more than $10,000 per patient prevented from developing [full-blown] TB disease. And because of improvements in compliance, we are actually preventing more cases. This treatment can save money as well as lives," Aspler said.

The study was expected to be presented Tuesday at the American Thoracic Society's International Conference, in Toronto.

Currently, about 2 billion people worldwide are believed to have latent, or dormant, TB. Of those, 8 million to 9 million will develop TB each year, and 1.6 million of them will die.

TB is most prevalent in developing countries, where Rifampin is offered at a subsidized cost through the Global Drug Facility of the World Health Organization. Not only is Rifampin less expensive, it has better patient compliance than Isoniazid due to the shorter treatment time, according to Aspler.

"While Isoniazid therapy is 90 percent effective for those who complete it, in reality, fewer than 50 percent do," Aspler said. This low compliance rate can have serious health consequences for patients who fail to complete treatment and for those they later infect.

Previous research and experience suggests that a four-month treatment program improves patient compliance by 20 percent to 25 percent, and reduces the risk of serious side effects such as liver damage.

"The next step in research is a major phase III clinical trial of efficacy -- ideally in HIV-infected and non-infected patients and in low-income settings where tuberculosis is the leading cause of death in people living with HIV," Aspler said.

More information

The National Institute of Allergy and Infectious Diseases has more about TB.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, May 20, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New chemical can kill latent tuberculosis bacteria
2. Rifampin: Latent TB treatment saves time money and lives
3. Surgery for severe obesity saves lives
4. Early Breast Cancer Detection Saves Lives
5. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
6. iPlan(R) Automatic Segmentation Saves 25 Minutes of Treatment Planning Time for Each Prostate Cancer Patient at the University of Nebraska Medical Center
7. Fetal Surgery Saves Baby After Early Water Break
8. Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions
9. Wal-Mart Saves Customers More Than $1 Billion On Prescription Drugs
10. Pro Football Hall of Fame Member Jim Kelly Urges Congress to Approve the Newborn Screening Saves Lives Act
11. American College of Medical Genetics Commends the Signing of the Newborn Screening Saves Lives Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Atlanta, GA (PRWEB) , ... August 16, 2017 , ... ... the new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... The list represents a unique look at the most successful companies within the American ...
(Date:8/16/2017)... ... 2017 , ... In 1987, McDaniel & Durrett, P.C., a ... this year, and they’re marking the milestone by undertaking a significant office makeover, ... , It stands to reason that, given the central importance of gynecology to ...
(Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , a ... today announced Cumberland Skin Surgery and Dermatology has joined the company ... in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin cancer ...
(Date:8/16/2017)... Island, NY (PRWEB) , ... August 16, 2017 , ... ... with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical ... takes much of the guesswork out of a needle stick and more importantly, helps ...
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, ... Connolly 2017 Top Doctor. The annual list identifies the nation’s top physicians, in a ... has made it to the top of Castle Connolly’s coveted ranking. , Castle Connolly ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017 AccuGenomics, Inc., a diagnostic ... today announced that the company has provided an AccuKit ... North Carolina at Chapel Hill and to Qura Therapeutics ... characterize and quantify HIV reservoir and viral expression in ... The HIV Cure Center is a joint initiative between ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/10/2017)... 10, 2017  Physical Rehabilitation Network (PRN), acquired the long-standing ... Lakewood, Colorado . The reputable clinic will continue to ... DPT with his staff of four clinicians. Lipkin received his ... brings over 10 years of experience with a strong background ... PT marks the 10th PRN clinic in and around the ...
Breaking Medicine Technology: